National Human Genome Research Institute Refocuses Extramural Research
The National Institutes of Healths National Human Genome Research Institute (NHGRI) is restructuring its extramural research program and making other organizational changes to accelerate the application of genomics to medicine.
The National Institutes of Health’s National Human Genome Research Institute (NHGRI) is restructuring its extramural research program and making other organizational changes to accelerate the application of genomics to medicine.
The reorganization, announced on Sept. 10, splits NHGRI’s extramural research unit into four new divisions. The Division of Genome Sciences will fund basic genomics research, technology development, and large-scale sequencing efforts; the Division of Genomic Medicine will focus on applying genomics to medicine and clinical care; the Division of Genomics & Society will oversee an expanded effort to understand the ethical, legal, and social implications of genomics; and the Division of Extramural Operations will manage grant administration and reviews.
“This reorganization reflects the expanding scope of genomics research, as described in NHGRI’s new strategic vision published in Nature last year,” NHGRI Director Eric D. Green says. “The mission of the institute has dramatically evolved from the singular focus on the Human Genome Project, for which NHGRI was created, to pursuing an exciting and broad set of opportunities for using genomics to advance medical science and improve human health.”
As part of the reorganization, two additional divisions—the Division of Policy, Communications & Education and the Division of Management—will be created from programs currently housed under the institute director’s office. The institute’s Division of Intramural Research will not undergo any changes. The reorganization will become effective on Oct. 1.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.